The morbidity and mortality associated with diabetic complications impose a huge socioeconomic burden worldwide. Therefore, the ultimate goal of managing diabetes mellitus (DM) is to lower the risk of macrovascular complications and highly morbid microvascular complications such as diabetic nephropathy (DN) and diabetic retinopathy (DR). Potential benefits of incretin-based therapies such as glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors on the diabetic macrovascular complications have been recently suggested, owing to their pleiotropic effects on multiple organ systems. However, studies primarily investigating the role of these therapies in diabetic microvascular complications are rare. Nevertheless, preclinical and limited clinical data suggest the potential protective effect of incretin-based agents against DN and DR via their anti-inflammatory, antioxidative, and antiapoptotic properties. Evidence also suggests that these incretin-dependent and independent beneficial effects are not necessarily associated with the glucose-lowering properties of GLP-1 RAs and DPP-4 inhibitors. Hence, in this review, we revisit the preclinical and clinical evidence of incretin-based therapy for DR and DN, the two most common, morbid complications in individuals with DM. In addition, the review discusses a few recent studies raising concerns of aggravating DR with the use of incretin-based therapies.

Citations

Citations to this article as recorded by  

• Efficacy and Safety of the Utilization of Dipeptidyl Peptidase IV Inhibitors in Diabetic Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials
  Moeber Mahzari, Muhannad Alqirnas, Moustafa Alhamadh, Faisal Alrasheed, Abdulrahman Alhabeeb, Wedad Al Madani, Hussain Aldera
  Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1425.     CrossRef
• Anti-Inflammatory Effects of GLP-1R Activation in the Retina
  Alessandra Puddu, Davide Maggi
  International Journal of Molecular Sciences.2022; 23(20): 12428.     CrossRef
• Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
  Anu Grover, Komal Sharma, Suresh Gautam, Srishti Gautam, Monica Gulati, Sachin Kumar Singh
  Current Diabetes Reviews.2021; 17(4): 397.     CrossRef
• SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
  Christopher El Mouhayyar, Ruba Riachy, Abir Bou Khalil, Asaad Eid, Sami Azar
  International Journal of Endocrinology.2020; 2020: 1.     CrossRef
• Novel therapeutic agents for the treatment of diabetic kidney disease
  Rachel E. Hartman, P.S.S. Rao, Mariann D. Churchwell, Susan J. Lewis
  Expert Opinion on Investigational Drugs.2020; 29(11): 1277.     CrossRef
• Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors
  Minyoung Lee, Jiyu Sun, Minkyung Han, Yongin Cho, Ji-Yeon Lee, Chung Mo Nam, Eun Seok Kang
  Diabetes Care.2019; 42(11): 2057.     CrossRef
• Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
  Jae Hyun Bae, Sunhee Kim, Eun-Gee Park, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
  Endocrinology and Metabolism.2019; 34(1): 80.     CrossRef
• Serum adipocytokines are associated with microalbuminuria in patients with type 1 diabetes and incipient chronic complications
  Tomislav Bulum, Marijana Vučić Lovrenčić, Martina Tomić, Sandra Vučković-Rebrina, Vinko Roso, Branko Kolarić, Vladimir Vuksan, Lea Duvnjak
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(1): 496.     CrossRef
• Protective Effects of Incretin Against Age-Related Diseases
  Di Zhang, Mingzhu Ma, Yueze Liu
  Current Drug Delivery.2019; 16(9): 793.     CrossRef
• The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin
  Annayya R. Aroor, Camila Manrique-Acevedo, Vincent G. DeMarco
  Cardiovascular Diabetology.2018;[Epub]     CrossRef

Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family, and GLP-1 receptor agonists (RAs) have been introduced as a new class of antidiabetic medications in the past decade. The benefits of GLP-1 RAs are derived from their pleiotropic effects, which include glucose-dependent insulin secretion, suppressed glucagon secretion, and reduced appetite. Moreover, GLP-1 RAs also exert beneficial roles on multiple organ systems in which the GLP-1 receptors exist, including the cardiovascular system. Cardiovascular effects of GLP-1 RAs have been of great interest since the burden from cardiovascular diseases (CVD) has been unbearably increasing in a diabetic population worldwide, despite strict glycemic control and advanced therapeutic techniques to treat CVD. Preclinical studies have already demonstrated the beneficial effects of GLP-1 on myocardium and vascular endothelium, and many clinical studies evaluating changes in surrogate markers of CVD have suggested potential benefits from the use of GLP-1 RAs. Data from numerous clinical trials primarily evaluating the antihyperglycemic effects of multiple GLP-1 RAs have also revealed that changes in most CVD risk markers reported as secondary outcomes have been in favor of GLP-1 RAs treatment. However, to date, there is only one randomized clinical trial of GLP-1 RAs (the ELIXA study) evaluating major cardiovascular events as their primary outcomes, and in this study, a neutral cardiovascular effect of lixisenatide was observed in high-risk diabetic subjects. Therefore, the results of ongoing CVD outcome trials with the use of GLP-1 RAs should be awaited to elucidate the translation of benefits previously seen in CVD risk marker studies into large clinical trials with primary cardiovascular outcomes.

Citations

Citations to this article as recorded by  

• Cardioprotective Actions of a Glucagon‐like Peptide‐1 Receptor Agonist on Hearts Donated After Circulatory Death
  Sachiko Kadowaki, M. Ahsan Siraj, Weiden Chen, Jian Wang, Marlee Parker, Anita Nagy, Chun‐Po Steve Fan, Kyle Runeckles, Jing Li, Junko Kobayashi, Christoph Haller, Mansoor Husain, Osami Honjo
  Journal of the American Heart Association.2023;[Epub]     CrossRef
• The role of dipeptidyl peptidase-IV in abdominal aortic aneurysm pathogenesis: A systematic review
  Elisha Ngetich, Pierfrancesco Lapolla, Anirudh Chandrashekar, Ashok Handa, Regent Lee
  Vascular Medicine.2022; 27(1): 77.     CrossRef
• Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors
  Jasna Klen, Vita Dolžan
  International Journal of Molecular Sciences.2022; 23(7): 3451.     CrossRef
• Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials
  Jing Qin, Li Song
  BMC Endocrine Disorders.2022;[Epub]     CrossRef
• Role of G-protein coupled receptor (GPCRs)/(GPR-120) as an agonists in diabetic wound healing
  Jagat Pal Yadav, Dinesh Kumar Patel, Prateek Pathak, Maria Grishina
  Obesity Medicine.2022; 36: 100466.     CrossRef
• Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms
  Bruno Vergès, Victor Aboyans, Denis Angoulvant, Pierre Boutouyrie, Bertrand Cariou, Fabien Hyafil, Kamel Mohammedi, Pierre Amarenco
  Cardiovascular Diabetology.2022;[Epub]     CrossRef
• Changing Fields-Diabetes Medications Invading the Cardiovascular Space
  Lauren D. Breite, Mackenzie Steck, Brandon Tate Cutshall, Samarth P. Shah, Brandon E. Cave
  Current Problems in Cardiology.2021; 46(3): 100736.     CrossRef
• PEGDA/HA mineralized hydrogel loaded with Exendin4 promotes bone regeneration in rat models with bone defects by inducing osteogenesis
  Wei Liu, Xiaowei Jing, Zhiwen Xu, Chong Teng
  Journal of Biomaterials Applications.2021; 35(10): 1337.     CrossRef
• Metabolite G-Protein Coupled Receptors in Cardio-Metabolic Diseases
  Derek Strassheim, Timothy Sullivan, David C. Irwin, Evgenia Gerasimovskaya, Tim Lahm, Dwight J. Klemm, Edward C. Dempsey, Kurt R. Stenmark, Vijaya Karoor
  Cells.2021; 10(12): 3347.     CrossRef
• PPG neurons in the nucleus of the solitary tract modulate heart rate but do not mediate GLP-1 receptor agonist-induced tachycardia in mice
  Marie K. Holt, Daniel R. Cook, Daniel I. Brierley, James E. Richards, Frank Reimann, Alexander V. Gourine, Nephtali Marina, Stefan Trapp
  Molecular Metabolism.2020; 39: 101024.     CrossRef
• A glycosylated Fc‐fused glucagon‐like peptide‐1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide
  In Bok An, Mi Sun Byun, Sang In Yang, Yuri Choi, Jung Won Woo, Hak Chul Jang, Young Chul Sung
  Diabetes, Obesity and Metabolism.2020; 22(8): 1455.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials
  Elodie M. Varin, Brent A. McLean, Julie A. Lovshin
  Canadian Journal of Diabetes.2020; 44(1): 68.     CrossRef
• Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors
  Alexandros Sachinidis, Dragana Nikolic, Anca Pantea Stoian, Nikolaos Papanas, Omer Tarar, Ali A. Rizvi, Manfredi Rizzo
  Metabolism.2020; 111: 154343.     CrossRef
• GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1β-induced metabolic disturbance and mitochondrial dysfunction
  Lili Zhang, Jiali Tian, Sujuan Diao, Guowei Zhang, Mochao Xiao, Dong Chang
  Chemico-Biological Interactions.2020; 332: 109252.     CrossRef
• Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
  Alina Yu. Babenko, Daria A. Savitskaya, Yulia A. Kononova, Aleksandra Yu. Trofimova, Anna V. Simanenkova, Elena Yu. Vasilyeva, Evgeny V. Shlyakhto
  Journal of Diabetes Research.2019; 2019: 1.     CrossRef
• Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity
  Ekaterina V. Tikhonenko, Alina Y. Babenko, Evgeny V. Shlyakhto
  Obesity and metabolism.2019; 15(4): 22.     CrossRef
• Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials
  Yu Mi Kang, Yun Kyung Cho, Jiwoo Lee, Seung Eun Lee, Woo Je Lee, Joong-Yeol Park, Ye-Jee Kim, Chang Hee Jung, Michael A. Nauck
  Diabetes & Metabolism Journal.2019; 43(4): 410.     CrossRef
• Diabetes, Incretin Therapy and Thoracic Aortic Aneurysm – What Does the Evidence Show?
  Camilla Krizhanovskii , Anders Franco-Cereceda
  Current Vascular Pharmacology.2019; 17(5): 432.     CrossRef
• Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
  Gül Bahtiyar, Jean Pujals-Kury, Alan Sacerdote
  Current Diabetes Reports.2018;[Epub]     CrossRef
• Efficacy From Strange Sources
  Lawrence J. Lesko
  Clinical Pharmacology & Therapeutics.2018; 103(2): 253.     CrossRef
• Exogenous SERP1 attenuates restenosis by restoring GLP-1 receptor activity in diabetic rats following vascular injury
  Lishuai Feng, Jianbo Wang, Xu Ma
  Biomedicine & Pharmacotherapy.2018; 103: 290.     CrossRef
• Exenatide exhibits anti‐inflammatory properties and modulates endothelial response to tumor necrosis factor α‐mediated activation
  Wojciech Garczorz, Enrique Gallego‐Colon, Agnieszka Kosowska, Agnieszka Kłych‐Ratuszny, Michał Woźniak, Wiesław Marcol, K.J. Niesner, Tomasz Francuz
  Cardiovascular Therapeutics.2018;[Epub]     CrossRef
• Molecular and clinical roles of incretin-based drugs in patients with heart failure
  Bassant Orabi, Rasha Kaddoura, Amr S. Omar, Cornelia Carr, Abdulaziz Alkhulaifi
  Heart Failure Reviews.2018; 23(3): 363.     CrossRef
• The effects of Exendin-4 on bone marrow-derived mesenchymal cells
  Paola Luciani, Benedetta Fibbi, Benedetta Mazzanti, Cristiana Deledda, Lara Ballerini, Alessandra Aldinucci, Susanna Benvenuti, Riccardo Saccardi, Alessandro Peri
  Endocrine.2018; 60(3): 423.     CrossRef
• Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic
  David M. Williams, Natasha Shrikrishnapalasuriyar, Waheeba Syed, Win L. Yin, Richard Chudleigh, Stephen C. Bain, David E. Price, Jeffrey W. Stephens
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2018; 12(6): 1079.     CrossRef
• Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome
  Maja Ðanić, Bojan Stanimirov, Nebojša Pavlović, Svetlana Goločorbin-Kon, Hani Al-Salami, Karmen Stankov, Momir Mikov
  Frontiers in Pharmacology.2018;[Epub]     CrossRef
• Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development
  Andrew J. Krentz, Gerardo Rodriguez-Araujo
  Pharmaceutical Medicine.2017; 31(6): 399.     CrossRef
• Articles inEndocrinology and Metabolismin 2016
  Won-Young Lee
  Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
• GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
  Rafael Simó, Cristina Hernández
  Diabetes.2017; 66(6): 1453.     CrossRef
• GLP-1 receptor agonists and heart failure in diabetes
  André J. Scheen
  Diabetes & Metabolism.2017; 43: 2S13.     CrossRef
• Effects of Incretin-Based Therapies on Diabetic Microvascular Complications
  Yu Mi Kang, Chang Hee Jung
  Endocrinology and Metabolism.2017; 32(3): 316.     CrossRef
• Historique des études cardiovasculaires : de l’UGDP… aux dernières études
  A.-J. Scheen
  Médecine des Maladies Métaboliques.2017; 11: 2S15.     CrossRef
• Cardiovascular safety and benefits of GLP-1 receptor agonists
  Niels B. Dalsgaard, Andreas Brønden, Tina Vilsbøll, Filip K. Knop
  Expert Opinion on Drug Safety.2017; 16(3): 351.     CrossRef

Acromegaly is a slowly progressing condition resulting from excess growth hormone (GH), generally caused by a GH-secreting pituitary adenoma. Cancer is the third most common cause of mortality in patients with acromegaly, and insulin-like growth factor 1 (IGF-1) is known to influence tumor formation by increasing cell proliferation and inhibiting apoptosis. Multiple myeloma (MM) is a plasma cell neoplasm, and previous studies have suggested the possible role of IGF-1 in its development of MM. However, no cases of acromegaly accompanied with MM have been reported in Asia to date. We here report the case of a 58-year-old woman with acromegaly accompanied with MM who presented with longstanding acromegalic manifestations resulting from a GH-secreting pituitary adenoma and also exhibited anemia, a reversed albumin/globulin ratio, and plasmacytosis on bone marrow examination. Because IGF-1 has been suggested to play an important role in the development and progression of MM, the patient promptly underwent surgical removal of the pituitary adenoma via a transsphenoidal approach. Since there is currently no consensus on therapeutic guidelines and suggested prognosis for MM with acromegaly, long-term follow-up of such cases is needed.

Citations

Citations to this article as recorded by  

• Co-Occurrence of Acromegaly and Hematological Disorders: A Myth or Common Pathogenic Mechanism
  Prakamya Gupta, Pinaki Dutta
  Integrative Medicine International.2017; 4(1-2): 94.     CrossRef